ArabinoFuranosylGuanine [18F]F-AraG

Preclinical

ArabinoFuranosylGuanine [18F]F-AraG is one of 45 therapeutic programs targeting Advanced Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced CancerRecruiting

Advanced CancerPreclinical

Recruiting

Competition

Competitive Landscape

67 competitors in Advanced Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

12 2

Taxol

Teva

Phase 2

12 3

Gemzar

Johnson & Johnson

Phase 2

8 4

Camptosar

Pfizer

Phase 2

8 5

Opdivo

Bristol-Myers Squibb

Phase 2

6 6

Verzenio

Eli Lilly

Phase 2

4 7

Elunate

Takeda

Phase 2

1 8

Taxotere

AAvyxa

Phase 2

9 9

Torisel

PPrism Pharmaceuticals

Phase 2

5 10

Paraplatin

AAvyxa

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Advanced Cancer

NCT05663710

Clinical

Trials by Indication[1]

Advanced Cancer1 trial

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT05663710·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ArabinoFuranosylGuanine [18F]F-AraG. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ArabinoFuranosylGuanine [18F]F-AraG. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: MM.D. Anderson Cancer Center

ArabinoFuranosylGuanine [18F]F-AraG

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Advanced Cancer1 trial

References

Drug Info

Quick Facts

Related News